cryptocurrency vs normal currency, Reviews

Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".At present, the market has also reached a very critical stage. If the large-cap stocks of heavyweights don't make efforts to push the index to a higher level, the short-term risk is relatively large in terms of the current position of CSI 2000 and micro-cap stocks. For example, the CSI 2000 index closed at 2635.58 today, and the high point in January 2022 was 2700.24, which is very close. It has not crossed this high point for more than two years, which shows that the pressure here is very great. If the market does not continue to launch upward, then it is impossible to complete an effective breakthrough by relying on small-cap stocks themselves, and it is impossible to get out of the independent market. Once the platform is effectively established, a larger level of space will be opened, and small-cap stocks will hopefully step out of a larger level of market. Otherwise, this wave of sharp rebound may stop here.Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.

The latest news of personal pension fund, incremental funds are coming!Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.

If we can continue to cut interest rates in December, it will undoubtedly be a big plus for A shares, and the pressure on the exchange rate will be further reduced, which may become a turning point in the short term.The latest news of personal pension fund, incremental funds are coming!So will heavyweights and large-cap stocks exert their strength? Looking at the trend of SSE 50, it is still very possible, because at present, the monthly trend of SSE 50 index is intact, and the index remains above the offensive line and above the long-term trend line. At present, it has the foundation to start a big market. Looking back, the index must remain above the monthly offensive line in all big markets, so this is a prerequisite. Since it is also available now, we can certainly expect something.